Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 137-142 , May 2007

Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes

  • Ildiko Lingvay

      Affiliations

    • Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    • Corresponding Author InformationCorresponding author. University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, MC 8858, Dallas, TX 75390, USA. Tel.: +1 214 648 2779; fax: +1 214 648 4854.
    • ,
  • Philip Raskin

      Affiliations

    • Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    • ,
  • Lidia S. Szczepaniak

      Affiliations

    • Division of Hypertension, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
    • Department of Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA

Received 26 January 2007 ,Accepted 11 February 2007.

References 

  1. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes. 2002;51:3025–3032
  2. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52:1364–1370
  3. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006;355:2297–2307
  4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology (Baltimore, MD). 2004;40:1387–1395
  5. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology. 2005;100:1082–1090
  6. Comar KM, Sterling RK. Review article: Drug therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2006;23:207–215
  7. Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis—A preliminary report. Indian Journal of Gastroenterology. 2004;23:12–15
  8. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2005;41:1313–1321
  9. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging. 1995;5:281–285
  10. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss. Diabetes and Metabolism. 2000;26:98–106
  11. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–894
  12. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802
  13. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Alimentary Pharmacology & Therapeutics. 2004;20:23–28
  14. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (Baltimore, MD). 2004;39:188–196
  15. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906
  16. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2005;21:871–879
  17. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Annals of Internal Medicine. 1997;126:137–145
  18. Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2006;12:2161–2167
  19. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, et al. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. American Journal of Physiology. 1999;276:E977–E989
  20. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. American Journal of Physiology. 2005;288:E462–E468
  21. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169–2176
  22. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006;29:1845–1850
  23. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2004;19:537–544
  24. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: Assessment of variability in pathologic interpretations. Modern Pathology. 1998;11:560–565

PII: S1056-8727(07)00017-7

doi: 10.1016/j.jdiacomp.2007.02.005

Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 137-142 , May 2007

Article Tools

* Image Usage & Resolution